Abstract
A novel bitriazolyl acyclonucleoside was discovered to exhibit powerful antiproliferative effects on different cancer cell lines through caspase-dependent apoptosis and at the same time stimulate the immune response in dendritic cells via Toll-like receptor 7 (TLR7) signaling. This promising compound with dual anticancer and immunomodulatory activity may represent a new generation of highly efficacious drug candidates for use in cancer therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology
-
Apoptosis / drug effects
-
Cell Line, Tumor
-
Dendritic Cells / drug effects
-
Dendritic Cells / immunology
-
Dendritic Cells / metabolism
-
Drug Resistance, Neoplasm
-
Drug Screening Assays, Antitumor
-
Humans
-
Immunologic Factors / chemical synthesis*
-
Immunologic Factors / chemistry
-
Immunologic Factors / pharmacology
-
Interleukin-6 / biosynthesis
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / metabolism
-
Mice
-
Mice, Knockout
-
Nucleosides / chemical synthesis*
-
Nucleosides / chemistry
-
Nucleosides / pharmacology
-
Structure-Activity Relationship
-
Toll-Like Receptor 7 / genetics
-
Toll-Like Receptor 7 / metabolism
-
Triazoles / chemical synthesis*
-
Triazoles / chemistry
-
Triazoles / pharmacology
Substances
-
Antineoplastic Agents
-
Immunologic Factors
-
Interleukin-6
-
Membrane Glycoproteins
-
Nucleosides
-
Tlr7 protein, mouse
-
Toll-Like Receptor 7
-
Triazoles